Theriva Biologics (TOVX) has announced encouraging top-line results from its VIRAGE trial, sending its stock up over 40% to $1.92 in premarket trading Wednesday.
VIRAGE is a phase IIb trial testing the company's lead drug candidate, VCN-01, in combination with standard of care (SoC) chemotherapy (gemcitabine and nab-paclitaxel), as a first-line treatment for patients with metastatic pancreatic cancer - a group for whom this chemotherapy is the recommended first-line treatment option.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com